drugset / Trial / NCT06607939
ORB-021 In Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to determine if an investigational new drug, named ORB-021, developed by Orionis Biosciences is safe and can be tolerated in people diagnosed with an advanced solid tumor. The study also aims to find the biologically optimal dose of the study medicine by assessing the safety and potential activity in the treatment of solid tumors. There are three phases to this study: screening, treatment and end of treatment.
Timeline
- Start
- 2024-11-21
- Primary completion
- 2026-05-29
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ORB-021 | Protein / enzyme biologic | — | Intravenous |
Indications
No indication recorded.